[The serum levels of soluble interleukin-2 receptor in patients with malignant lymphocytic proliferative disorders].
OBJECTIVE
To explore the changes of serum levels of soluble interleukin-2 receptor (sIL-2R) in lymphocytic malignancies and its clinical implication.


METHODS
The serum levels of sIL-2R were measured in 60 cases of patients with various malignant lymphocytic proliferative disorders by using ELISA method. At the same time, the ratio of CD4+/CD8+ of peripheral blood mononuclear cells was also determined in 43 patients by using fluorescence activated cell sorter(FACS).


RESULTS
The serum levels of sIL-2R in patients with multiple myeloma(MM), non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia(ALL) were significantly higher than that of normal value. The ratio of CD4+/CD8+ measured in 43 patients were markedly lower than that of normal value. In MM, NHL and ALL patients, the higher values of sIL-2R were revealed in severe cases or late stage of these diseases. The levels of sIL-2R were independant of the infection in these cases.


CONCLUSIONS
sIL-2R levels significantly elevated as the disease progressing, and the immune function decreasing, and the sIL-2R level may be used as an effective clinical marker.
Xu
J
J
Zhongshan Hospital, Shanghai Medical University.
Wang
B
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D016516:CD4-CD8 Ratio; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood*; D015375:Receptors, Interleukin-2 / Q000097:blood*
D015375:Receptors, Interleukin-2